New and Emerging Treatments for Newly Diagnosed and R/R CLL/SLL: Targeted Inhibitors - Dr. Susan O'Brien

[lankisterguy]

This webcast on new and emerging treatments for newly diagnosed and R/R CLL/SLL with a focus on targeted inhibitors, presented by Dr. Susan O'Brien is intended for medical professionals and uses moderate "Med-Speak."

So only recommended for those accustomed to the medical language. But if you can follow it, it has lots of excellent detailed comparisons

-

Len

-

hmpeducation.com/content/ac...

hmpeducation.com/content/do...

This accredited, on-demand activity features a presentation that discusses the mechanism of action, safety/efficacy data, and potential drug-drug interactions associated with Bruton tyrosine kinase (BTK) inhibitors.

Learning Objectives

After participating in this activity, learners should be better able to:

• Assess the current treatment options for CLL beyond the current chemoimmunotherapy (CIT) standard

• Evaluate the mechanism of action, safety/efficacy data, and potential drug-drug interactions associated with bruton tyrosine kinase (BTK) inhibitors

• Incorporate guideline recommendations for cytogenetic analysis and minimal residual disease (MRD) monitoring into the care of patients with CLL/SLL

[CycleWonder]

Thank you. I will listen to this today.

[MGirl-Aust]

Thanks Len, great presentation - Dr O’Brien summarised a lot of the trial data for frontline CLL therapy in a relatively short video 😊.